Prosthesis for placement at a luminal OS

Information

  • Patent Grant
  • 8926685
  • Patent Number
    8,926,685
  • Date Filed
    Tuesday, April 27, 2010
    14 years ago
  • Date Issued
    Tuesday, January 6, 2015
    9 years ago
Abstract
An embodiment of the invention provides a prosthesis delivery system comprising a delivery catheter having an expandable member and a prosthesis carried over the expandable member. The prosthesis includes a radially expandable scaffold section and at least two anchors extending axially from an end thereof; and means for capturing at least the anchors to prevent the anchors from divaricating from the expandable member as the catheter is advanced through a patient's vasculature.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

Embodiments of the present invention relate generally to medical devices and methods. More particularly, embodiments of the present invention relate to the structure and deployment of a segmented stent at a luminal os at a branching point in the vasculature or elsewhere.


Maintaining the patency of body lumens is of interest in the treatment of a variety of diseases. Of particular interest to the present invention are the transluminal approaches to the treatment of body lumens. More particularly, the percutaneous treatment of atherosclerotic disease involving the coronary and peripheral arterial systems. Currently, percutaneous coronary interventions (PCI) often involve a combination of balloon dilation of a coronary stenosis (i.e. a narrowing or blockage of the artery) followed by the placement of an endovascular prosthesis commonly referred to as a stent.


A major limitation of PCI/stent procedures is restenosis, i.e., the re-narrowing of a blockage after successful intervention typically occurring in the initial three to six months post treatment. The recent introduction of drug eluting stents (DES) has dramatically reduced the incidence of restenosis in coronary vascular applications and offers promise in peripheral stents, venous grafts, arterial and prosthetic grafts, as well as A-V fistulae. In addition to vascular applications, stents are being employed in treatment of other body lumens including the gastrointestinal systems (esophagus, large and small intestines, biliary system and pancreatic ducts) and the genital-urinary system (ureter, urethra, fallopian tubes, vas deferens).


Treatment of lesions in and around branch points generally referred to as bifurcated vessels, is a developing area for stent applications, particularly, since 10% of all coronary lesions involve bifurcations. However, while quite successful in treating arterial blockages and other conditions, most stent designs are challenged when used at a bifurcation in the blood vessel or other body lumen. Presently, many different strategies are employed to treat bifurcation lesions with currently available stents all of which have major limitations.


One common approach is to place a conventional stent in the main or larger body lumen over the origin of the side branch. After removal of the stent delivery balloon, a second wire is introduced through a cell in the wall of the deployed stent and into the side branch. A balloon is then introduced into the side branch and inflated to enlarge the side-cell of the main vessel stent. This approach can work well when the side branch is relatively free of disease, although it is associated with increased rates of abrupt closure due to plaque shift as well as increased rates of late re-restenosis.


Another commonly employed strategy is the ‘kissing balloon’ technique in which separate balloons are positioned in the main and side branch vessels and simultaneously inflated to deliver separate stents simultaneously. This technique is thought to prevent plaque shift.


Other two stent approaches including Culotte, T-Stent and Crush Stent techniques have been employed as well. When employing a T-stent approach, the operator deploys a stent in the side branch followed by placement of a main vessel stent. This approach is limited by anatomic variation (angle between main and side branch) and inaccuracy in stent positioning, which together can cause inadequate stent coverage of the sidebranch os. More recently, the Crush approach has been introduced in which the side-vessel stent is deployed across the os with portions in both the main and side branch vessels. The main vessel stent is then delivered across the origin of the side branch and deployed, which results in crushing a portion of the side branch stent against the wall of the main vessel. Following main-vessel stent deployment, it is difficult and frequently not possible to re-enter the side branch after crush stenting. Unproven long-term results coupled with concern regarding the inability to re-enter the side branch, malapposition of the stents against the arterial wall and the impact of three layers of stent (which may be drug eluting) opposed against the main vessel wall has limited the adoption of this approach.


These limitations have led to the development of stents specifically designed to treat bifurcated lesions. One approach employs a stent design with a side opening for the branch vessel which is mounted on a specialized delivery balloon. The specialized balloon delivery system accommodates wires for both the main and side branch vessels. The system is tracked over both wires which provides a mean to axially and radially align the stent/stent delivery system. The specialized main vessel stent is then deployed and the stent delivery system removed while maintaining wire position in both the main and side branch vessels. The side branch is then addressed using kissing balloon or by delivering and an additional stent to the side branch. Though this approach has many theoretic advantages, it is limited by difficulties in tracking the delivery system over two wires (Vardi et al, U.S. Pat. Nos. 6,325,826 and 6,210,429).


Another approach, of particular interest to the present invention, includes the use of fronds, or fingers extending from the scaffolding of a side branch stent to facilitate positioning of the stent at a bifurcated lesion. This approach is described in detail in co-pending commonly assigned application Ser. No. 10/807,643 the full disclosure of which is incorporated herein.


However while above approach has significant promise, conventional stent delivery systems, such as balloon catheters, can have difficulty managing the fronds during delivery. In such conventional systems, the stent is usually crimped onto the balloon of the balloon catheter. While fine for many conventional stent designs, conventional balloons systems may not always prevent the fronds on a stent from separating from the balloon as the catheter is advanced through curved portions of the vasculature, such as those found in the circumflex coronary artery.


For these reasons, it would be desirable to provide improved systems and methods for delivering stents, particularly stents with fronds or other protruding anchoring elements at one end, to treat body lumens at or near the location of an os between a main body lumen and a side branch lumen, typically in the vasculature, and more particularly in the arterial vasculature. It would be further desirable if such systems and methods could treat the side branch vessels substantially completely in the region of the os and that the prostheses in the side branches be well-anchored at or near the os.


DESCRIPTION OF THE RELATED ART

Stent structures intended for treating bifurcated lesions are described in U.S. Pat. Nos. 6,599,316; 6,596,020; 6,325,826; and 6,210,429. Other stents and prostheses of interest are described in the following U.S. Pat. Nos. 4,994,071; 5,102,417; 5,342,387; 5,507,769; 5,575,817; 5,607,444; 5,609,627; 5,613,980; 5,669,924; 5,669,932; 5,720,735; 5,741,325; 5,749,825; 5,755,734; 5,755,735; 5,824,052; 5,827,320; 5,855,598; 5,860,998; 5,868,777; 5,893,887; 5,897,588; 5,906,640; 5,906,641; 5,967,971; 6,017,363; 6,033,434; 6,033,435; 6,048,361; 6,051,020; 6,056,775; 6,090,133; 6,096,073; 6,099,497; 6,099,560; 6,129,738; 6,165,195; 6,221,080; 6,221,098; 6,254,593; 6,258,116; 6,264,682; 6,346,089; 6,361,544; 6,383,213; 6,387,120; 6,409,750; 6,428,567; 6,436,104; 6,436,134; 6,440,165; 6,482,211; 6,508,836; 6,579,312; and 6,582,394.


SUMMARY OF THE INVENTION

Embodiments of the present invention provide improved delivery systems for the delivery and placement of stents or other prosthesis within a body lumen, particularly within a bifurcated body lumen and more particularly at an os opening from a main body lumen to a branch body lumen. The delivery systems will be principally useful in the vasculature, most typically the arterial vasculature, including the coronary, carotid and peripheral vasculature; vascular grafts including arterial, venous, and prosthetic grafts, and A-V fistulae. In addition to vascular applications, embodiments of the present invention can also be configured to be used in the treatment of other body lumens including those in the gastrointestinal systems (e.g., esophagus, large and small intestines, biliary system and pancreatic ducts) and the genital-urinary system (e.g., ureter, urethra, fallopian tubes, vas deferens), and the like.


The stent or other prostheses to be delivered will usually comprise a proximal portion which can include anchoring components which can include anchors, fronds, petals or other independently deflectable element extending axially from a main or scaffold section of the stent. These anchoring components can expandably conform to and at least partially circumscribe the wall of the main body vessel to selectively and stably position the prosthesis within the side branch lumen. Further description of exemplary anchoring components and prostheses is found in co-pending application Ser. No. 10/897,643, the full disclosure of which has previously been incorporated herein by reference. Various embodiments of the present invention provide means for capturing or otherwise radially constraining the anchoring components during advancement of the stent through the vasculature (or other body lumen) to a target site and then releasing the anchoring components.


In a first aspect of the invention, a prosthesis delivery system comprises a delivery catheter having an expandable member and a prosthesis carried over the expandable member. The prosthesis has a radially expandable scaffold and at least two fronds extending axially from an end of the scaffold. The system also includes means for capturing the fronds to prevent them from divaricating from the expandable member as the catheter is advanced through a patient's vasculature. Divarication as used herein means the separation or branching of the fronds away from the delivery catheter. Various embodiment of the capture means prevent divarication by constraining and/or imparting sufficient hoop strength to the fronds to prevent them from branching from the expandable member during catheter advancement in the vasculature.


In one embodiment, the capturing means comprises a portion of the expandable member that is folded over the fronds where the folds protrude through axial gaps between adjacent fronds. In another embodiment, the capturing means comprises a cuff that extends over at least a portion of the fronds to hold them during catheter advancement. The cuff can be positioned at the proximal end of the prosthesis and can be removed by expansion of the expandable member to either plastically deform the cuff, break the cuff, or reduce the cuff in length axially as the cuff expands circumferentially. The cuff is then withdrawn from the target vessel. In yet another embodiment, the capturing means can comprise a tether which ties together the fronds. The tether can be configured to be detached from the fronds prior to expansion of the expandable member. In alternative embodiments, the tether can be configured to break or release upon expansion of the expandable member so as to release the fronds.


In an exemplary deployment protocol using the prosthesis delivery system, the delivery catheter is advanced to position the prosthesis at a target location in a body lumen. During advancement, at least a portion of the fronds are radially constrained to prevent divarication of the fronds from the delivery catheter. When the target location is reached, the radial constraint is released and the prosthesis is deployed within the lumen.


In various embodiments, the release of the fronds and expansion of the prosthesis can occur simultaneously or alternatively, the radial constraint can be released prior to expanding/deploying the prosthesis. In embodiments where the radial constraint comprises balloon folds covering the fronds or a cuff or tether, the constraint can be released as the balloon is inflated. In alternative embodiments using a cuff or tether, the cuff/tether can be withdrawn from the fronds prior to expansion of the scaffold.


Embodiments of the above protocol can be used to deploy the prosthesis across the os of a branch body lumen into the main body lumen. In such applications, the prosthesis can be positioned so that the scaffold lies within the branch body and at least two fronds extend into the main body lumen. The fronds are then circumferentially deformed to circumscribe at least a portion of the main vessel wall and open a passage through the fronds. At least three fronds extend into the main body lumen.


Radiopaque or other medical imaging visible markers can be placed on the prostheses and/or delivery balloon at desired locations. In particular, it may be desirable to provide radiopaque markers at or near the location on the prosthesis where the scaffold is joined to the circumferential fronds. Such markers will allow a transition region of the prosthesis between the scaffold and the fronds to be properly located near the os prior to scaffold expansion. The radiopaque or other markers for location the transition region on the prosthesis can also be positioned on a balloon or other delivery catheter. Accordingly, in one embodiment of the deployment protocol, positioning the prosthesis can include aligning a visible marker on at least one of the prosthesis and a delivery balloon with the os.


In various embodiments for deploying the prosthesis, the scaffold is expanded with a balloon catheter expanded within the scaffold. In some instances, the scaffold and the circumferential fronds may be expanded and deformed using the same balloon, e.g., the balloon is first used to expand the anchor, partially withdrawn, and then advanced transversely through the circumferential fronds where it is expanded for a second time. Alternatively, separate balloon catheters may be employed for expanding the scaffold within the side branch and deforming the circumferential fronds within the main body lumen.


By “expandably circumscribe,” it is meant that the fronds will extend into the main body lumen after initial placement of the scaffold within the branch body lumen. The circumferential fronds will be adapted to then be partially or fully radially expanded, typically by expansion of a balloon or other expandable element therein, so that the fronds deform outwardly and engage the interior of the main lumen wall.


The circumferential fronds will usually extend axially within the main vessel lumen for some distance after complete deployment. Thus, the contact between the fronds and the main vessel wall will usually extend both circumferentially (typically covering an arc equal to one-half or more of the circumference) and axially.


Expansion of the circumferential fronds at least partially within the main body lumen provides a generally continuous coverage of the os from the side body lumen to the main body lumen. Further and/or complete expansion of the circumferential fronds within the main body lumen may press the fronds firmly against the main body lumen wall and open up the fronds so that they do not obstruct flow through the main body lumen.


Usually, the prosthesis will include at least three circumferential fronds extending axially from the end of the scaffold. The circumferential fronds will have an initial length (i.e., prior to radial expansion of the scaffold) which is at least 1.5 times the width of the scaffold prior to expansion, typically being at least 2 times the width, more typically being at least 5 times the width, and often being 7 times the width or greater. The lengths will typically be at least 2 mm, preferably being at least 3 mm, and more preferably being at least 6 mm, depending on the diameter of the scaffold and prosthesis. The circumferential fronds will usually have a width which is expandable to accommodate the expansion of the scaffold, and the fronds may be “hinged” at their point of connection to the scaffold to permit freedom to adapt to the geometry of the main vessel lumen as the prosthesis is expanded. It is also possible that the fronds could be attached to the single point to the scaffold, thus reducing the need for such expandability. The fronds may be congruent, i.e., have identical geometries and dimensions, or may have different geometries and/or dimensions. In particular, in some instances, it may be desirable to provide fronds having different lengths and/or different widths. Again further description of the fronds may be found in co-pending application Ser. No. 10/807,643.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic illustration of a prosthesis constructed in accordance with the principles of the present invention.



FIG. 1A is a detailed view of an fronds of the prosthesis of FIG. 1, shown with the fronds deployed in broken line.



FIG. 2 is a cross-sectional view taken along line 2-2 of FIG. 1.



FIGS. 3A and 3B are lateral and cross sectional views illustrating an embodiment of a stent having fronds and an underlying deployment balloon having a fold configuration such that the balloon folds protrude through the spaces between the fronds.



FIGS. 4A and 4B are lateral and cross sectional views illustrating the embodiment of FIGS. 3A and 3B with the balloon folded over to capture the fronds.



FIGS. 5A-5C are lateral views illustrating the deployment of stent fronds using an underlying deployment balloon and a retaining cuff positioned over the proximal portion of the balloon. FIG. 5A shows pre-deployment, the balloon un-inflated; FIG. 5B shows deployment, with the balloon inflated; and FIG. 5C post-deployment, the balloon now deflated.



FIGS. 6A-6B are lateral views illustrating the change in shape of the cuff of during deployment of a stent with fronds, of FIG. 6A shows the balloon in an unexpanded state; and FIG. 6B shows the balloon in an expanded state, with the cuff expanded radially and shrunken axially.



FIGS. 6C-6D are lateral views illustrating an embodiment of a cuff configured to evert upon balloon inflation to release the fronds.



FIGS. 7A-7B are lateral views illustrating an embodiment of a tether for restraining the stent fronds.



FIGS. 8A-8B are lateral views illustrating an embodiment of a movable sleeve for restraining the stent fronds.



FIGS. 9A-9B, 10A-10B and 11A-11B illustrate deployment of a stent at an os between a main blood vessel and a side branch blood vessel in accordance with the principles of the methods of the present invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring now to FIGS. 1 and 2, an embodiment of a delivery system 5 of the present invention for the delivery of a stent to a bifurcated vessel can include a stent or other prosthesis 10 and a delivery catheter 30. Stent 10 can include at least a radially expansible scaffold section 12 and an anchor section 14 with one or more anchors 16 also known as fronds 16. In various embodiments, the anchor section 14 includes at least two axially aligned circumferential fronds 16, with three being illustrated. The radially expansible scaffold section 12 will typically be expandable by an expansion device such as a balloon catheter, but alternatively it can be self expandable. The scaffold section may be formed using a variety of conventional patterns and fabrication techniques as are well-described in the prior art.


Fronds 16, will usually extend axially from the scaffold section 12, as illustrated, but in some circumstances the fronds can be configured to extend helically, spirally, in a serpentine pattern, or other configurations. It is desirable, however, that the individual fronds be radially separable so that they can be independently folded, bent, and otherwise positioned within the main body lumen after the scaffold section 12 has been implanted within the branch body lumen. In the schematic embodiment of FIG. 1, the fronds 16 may be independently folded out in a “petal-like” configuration, forming petals 16p, as generally shown in broken line for one of the fronds in FIGS. 1 and 2.


In preferred embodiments, fronds 16 will be attached to the scaffold section 12 such that they can both bend and rotate relative to an axis A thereof, as shown in broken line in FIG. 1A. Bending can occur radially outwardly and rotation or twisting can occur about the axis A as the fronds are bent outwardly. Such freedom of motion can be provided by single point attachment joints as well as two point attachments or three-point attachments.


Referring now to FIGS. 3A-8, in various embodiments delivery system 5 can include a stent 210 having fronds 220 which are configured to be captured or otherwise radially constrained during advancement of the stent through the vasculature or other body lumen. As shown in FIGS. 3A-3B, fronds 220 can be separated by axial gaps or splits 230 along the length of the stent structure. Splits 230 can have a variety of widths and in various embodiments, can have a width between 0.05 to 2 times the width of the fronds, with specific embodiments of 0.05, 0.25, 0.5, 1 and 2 times the width of the fronds. Fronds 220 can be configured to have sufficient flexibility to be advanced through curved and/or tortuous vessels to reach the more distal portions of the vasculature such as distal portion of the coronary vasculature. This can be achieved through the selection of dimensions and/or material properties (e.g. flexural properties) of the fronds. For example, all or a portion of fronds 220 can comprise a resilient metal (e.g., stainless steel) or a superelastic material known in the art. Examples of suitable superelastic materials include various nickel titanium alloys known in the art such as Nitinol™.


It is desirable to have the fronds captured and held against the delivery catheter or otherwise restrained as the stent is advanced through the vasculature in order to prevent the fronds from divaricating or separating and branching from the scaffold section of the stent. Capture of the fronds and prevention of divarication can be achieved through a variety of means. For example, in various embodiments the capture means can be configured to prevent divarication by imparting sufficient hoop strength to the fronds, or a structure including the fronds, to prevent the fronds from separating and branching from the deployment balloon as the balloon catheter is advanced through the vascular including tortuous vasculature. In theses embodiments, the capture means are also configured to allow the fronds to have sufficient flexibility to be advanced through the vasculature as described above.


In an embodiment shown in FIGS. 3A-4B, the fronds can be captured under the flaps 242 of a deployment balloon 241 of a delivery balloon catheter 240. In this and related embodiments, the balloon 241 and stent 210 can be configured such that flaps 242 are substantially matched up or aligned with splits 230. This can achieved using alignment techniques known in the art (e.g., use of alignment fixtures) when the stent 220 is positioned over balloon 241. The flap material will initially extend or protruded through the splits, but is then folded over onto one or more fronds 220 to capture those fronds. In an embodiment, this can be achieved by partially inflating and then deflating the balloon, with folding done after the inflation or deflation. Folding can be done by hand or using a capture tube or overlying sleeve known in the art. Also in an embodiment, folding can be facilitated by the use of one or more preformed folds 243, also known as fold lines 243. Folds 243 can be formed using medical balloon fabrication methods known in the art such as mold blowing methods known in the art. In an embodiment using folds 243, folding can be achieved by inflating the balloon with the overlying fronds in place, so as to have the balloon flaps 242 protrude through splits 230, then the balloon is a deflated to have flaps 242 fold back over fronds 220 at fold lines 243.


Once stent 210 is properly positioned at the target vessel site, balloon 241 is at least partially inflated which unfurls flaps 242 covering fronds 220 so as to release the fronds. Once released, deployment balloon 241 can also be used to expand or otherwise deform the fronds 220 to deploy them in the selected vessel as is described herein. Alternatively, a second balloon can be used to expand and deploy the fronds as is also described herein.


To avoid pinching the balloon material of balloon 241 between layers of stent metal during the stent crimping process in one embodiment, fronds 220 can be configured such that they do not overlap when crimped down to a smaller diameter. This can be achieved by configuring the fronds to be sufficiently narrow so that crimping the stent to a smaller diameter does not cause them to overlap, or through the use of a crimping fixture or mandrel known in the art. In various embodiments, fronds 220 can be configured to have a selectable minimum split width 230w between splits 230 after crimping. This can be in the range of about 0.001 to about 0.2 inches with specific embodiments of 0.002, 0.005, 0.010, 0.025, 0.050 and 0.1 inches.


In another embodiment for using the delivery balloon catheter to capture the fronds, a section of the balloon 241 (not shown) can be configured to evert or fold back over a proximal portion of the stent and thus overly and capture the fronds. When the balloon is inflated, the overlying section of balloon material unfolds, releasing the fronds. The everted section of balloon can over all or any selected portion of the fronds. Eversion can be facilitated through the use of preformed folds described herein, in this case, the folds having a circumferential configuration. The folded section of balloon can be held in place by a friction fit or through the use of releasable low-strength heat bond or adhesive known in the art for bonding the balloon to the fronds. In one embodiment for positioning the everted section, the balloon is positioned inside the scaffold section of the stent and then partially inflated to have an end of the balloon protrude outside of the scaffold section, then the balloon is partially deflated and the everted section is rolled over the fronds and then the balloon is fully deflated to create a vacuum or shrink fit of the balloon onto the fronds.


In various embodiments, fronds 210 can also be captured by use of a cuff 250 extending from the proximal end 241p of delivery balloon 241 as is shown in FIGS. 5A-5C. In preferred embodiments the cuff is attached to the catheter at the proximal end 241p of the delivery balloon. In alternative embodiments, the cuff can be attached to a more proximal section of the catheter shaft such that there is an exposed section of catheter shaft between balloon and the cuff attachment point with the attachment point selected to facilitate catheter flexibility. In either approach, the cuff is fixed to the proximal end of the balloon 241p such that it overlies at least a portion of stent fronds 220.


After stent 210 is positioned at the target tissue site, the cuff releases the fronds allowing the stent to be deployed using the delivery balloon as is described herein. After releasing the fronds, the cuff can then be withdrawn prior to or along with the removal of the balloon catheter. In most embodiments, the entire catheter assembly including cuff, balloon, and catheter shaft are withdrawn proximally to fully release the fronds.


Release of the fronds by the cuff can be achieved through a variety of means. In one embodiment, cuff 250 can be configured such the frond tips 220t, slip out from the cuff when the balloon is deployed. Alternatively, the cuff my scored or perforated such that it breaks at least partially open upon balloon deployment so that it releases fronds 220. Accordingly, in such embodiments, cuff 250 can have one or more scored or perforated sections 250p. In such embodiments, portions of cuff 250 can be configured to break open at a selectable inflation pressure or at a selectable expanded diameter.


In various embodiments, cuff 250 can be configured such that it plastically deforms when the balloon is inflated and substantially retains its “inflated shape” 250is and “inflated diameter” 250id after the balloon is deflated is shown in FIGS. 5B and 5C. This can be achieved through the selection of plastically deformable materials for cuff 250 (e.g. plastically deformable polymers), the design of the cuff itself (e.g. cuff dimensions and shape) and combinations thereof. For example, a cuff fixed to the catheter shaft and having the same approximate internal diameter as the deployed stent may be folded over the stent fronds to constrain them (using conventional balloon folding techniques). That cuff may be unfolded when the stent deployment balloon is inflated and the fronds released. The cuff can then be withdrawn along with the balloon and catheter. In an alternative embodiment of a folded-over cuff, the cuff is relatively inelastic and has an internal diameter approximately that of the deployed stent.


Also the cuff can be configured such that it shortens axially as it is expanded by the deployment balloon or other expansion device. This can be accomplished by selecting the materials for cuff 250 such that cuff shrinks axially when it is stretched radially as is shown in FIGS. 6A and 6B. Accordingly, in one embodiment, the cuff can made of elastomeric material configured to shrink axially when stretched radially.


In another embodiment, all or a portion of the cuff can be configured to fold over or evert onto itself upon inflation of the balloon to produce an everted section 251 and so release the enveloped fronds as is shown in FIGS. 6C-6D. This can be facilitated by use of fold lines 252 described herein, as well as coupling the cuff to the balloon catheter. In one embodiment the cuff can be coaxially disposed over the proximal or distal end of the balloon catheter or even slightly in front of either end. This allows the cuff to disengage the fronds yet remain attached to the balloon catheter for easy removal from the vessel. In use, these and related embodiments allow the fronds to be held against the balloon to be radially constrained or captured during stent advancement and then easily released before, during or after balloon inflation to deploy the stent at the target site.


In various embodiments, all or a portion of cuff 250 can be fabricated from, silicones, polyurethanes (e.g., PEPAX) and other medical elastomers known in the art; polyethylenes; fluoropolymers; polyolefin; as well as other medical polymers known in the art. Cuff 250 can also be made of heat shrink tubing known in the art such as polyolefin or PTFE heat shrink tubing. These materials can be selected to produce a desired amount of plastic deformation for a selected stress (e.g. hoop stress from the inflation of deployment balloon). In particular embodiments, all or a portion of the materials comprising cuff 250 can be selected to have an elastic limit lower than forces exerted by inflation of the deployment balloon (e.g., the force exerted by a 3 mm diameter balloon inflated to 10 atms). Combinations of materials may be employed such that different portions of the cuff (e.g., the proximal and distal sections or the inner and outer surfaces) have differing mechanical properties including, but not limited to, durometer, stiffness and coefficient of friction. For example, in one embodiment the distal portion of the cuff can high a higher durometer or stiffness than a proximal portion of the cuff. This can be achieved by constructing the proximal portion of the cuff from a first material (e.g., a first elastomer) and the distal portion out of a second material (e.g. a second elastomer). Embodiments of the cuff having a stiffer distal portion facilitate maintaining the fronds in a restrained state prior to deployment. In another embodiment, at least a portion of an interior surface of the cuff can include a lubricous material. Examples of suitable lubricious materials include fluoropolymers such as PTFE. In a related embodiment, a portion of the interior of the cuff, e.g., a distal portion, can be lined with a lubricous material such as a fluoropolymer. Use of lubricous materials on the interior of the cuff aids in the fronds sliding out from under the cuff during balloon expansion.


Referring now to FIGS. 7A-7B, in another embodiment for restraining the fronds, a tether 260 can be placed over all or portion of fronds 220 so as to tie the fronds together. Similar to the use of cuff 250, tether 260 can be released by the expansion of the balloon 241. Accordingly, all or a portion of the tether can be configured to plastically deform upon inflation of balloon 241 so as to release the fronds. Alternatively, the tether can be configured to be detached from the fronds prior to expansion of the balloon. In one embodiment, this can be achieved via a pull wire, catheter or other pulling means coupled to the tether directly or indirectly.


In various embodiments, the tether can be a filament, cord, ribbon, etc. which would simply extend around the fronds to capture them like a lasso. In one embodiment the tether can comprise a suture or suture-like material that is wrapped around the fronds. One or both ends of the suture tether can be attachable to the balloon catheter 241. In another embodiment, tether 260 can comprise a band or sleeve that fits over fronds 220 and then expands with expansion of balloon 241. In this and related embodiments Tether 260 can also be attached to balloon catheter 241. Also, tether 260 can be scored or perforated so that a portion of the tether shears or otherwise breaks upon balloon inflation, thereby releasing the fronds. Further, the tether 260 can contain a radio-opaque other medical image visible marker 260m to allow the physician to visualize the position of the tether on the fronds, and/or determine if the tether is constraining the fronds.


Referring now to FIGS. 8A-8B, in other embodiments of the delivery system 10, the fronds can be constrained through the use of a removable sleeve 270 that can be cover all or a portion of fronds 220 during positioning of the stent at the target tissue site and then be removed prior to deployment of the fronds. In one embodiment, sleeve 270 can be slidably advanced and retracted over stent 210 including fronds 220. Accordingly, all or portions of sleeve 270 can be made from lubricous materials such as PTFE or silicone. Sleeve 270 can also include one or more radio-opaque or other imaging markers 275 which can be positioned to allow the physician to determine to what extent the sleeve is covering the fronds. In various embodiments, sleeve 270 can be movably coupled to catheter 240 such that the sleeve slides over either the outer or inner surface (e.g., via an inner lumen) of catheter 240. The sleeve can be moved through the use of a pull wire, hypotube, stiff shaft or other retraction means 280 known in the medical device arts. In one embodiment, sleeve 270 can comprise a guiding catheter or overtube as is known in the medical device arts.


Referring now to FIGS. 9A-11B, an exemplary deployment protocol for using delivery system 5 to deliver a stent having one or more fronds will be described. The order of acts in this protocol is exemplary and other orders and/or acts may be used. A delivery balloon catheter 30 is advanced within the vasculature to carry stent 10 having fronds 16 to an os O located between a main vessel lumen MVL and a branch vessel lumen BVL in the vasculature, as shown in FIGS. 9A and 9B. Balloon catheter 30 may be introduced over a single guidewire GW which passes from the main vessel lumen MVL through the os O into the branch vessel BVL. Optionally, a second guidewire (not shown) which passes by the os O in the main vessel lumen MVL may also be employed. Usually, the stent 10 will include at least one radiopaque marker 20 on stent 10 located near the transition region between the scaffold section 12 and the circumferential fronds 16. In these embodiments, the radiopaque marker 20 can be aligned with the os O, typically under fluoroscopic imaging.


During advancement, the fronds are radially constrained by a constraining means 250c described herein (e.g., a cuff or tether) to prevent divarication of the fronds from the delivery catheter. When the target tissue location is reached at os O or other selected location, the constraining means 250c is released by the expansion of balloon 32 or other constraint release means described herein (alternatively, the constraining means can be released prior to balloon expansion). Balloon 32 is then further expanded to implant the scaffold region 10 within the branch vessel lumen BVL, as shown in FIGS. 10A and 10B. Expansion of the balloon 32 also partially deploys the fronds 16, opening them in a petal-like manner, as shown in FIG. 10B, typically extending both circumferentially and axially into the main vessel lumen MVL. The fronds 16, however, are not necessarily fully deployed and may remain at least partially within the central region of the main vessel lumen MVL.


Various approaches can be used in order to fully open the fronds 16. In one embodiment, a second balloon catheter 130 can be introduced over a guidewire GW to position the balloon 132 within the petals, as shown in FIGS. 11A and 11B. Optionally, the first catheter 30 could be re-deployed, for example, by partially withdrawing the catheter, repositioning the guidewire GW, and then advancing the deflated balloon 32 transversely through the fronds 16 and then re-inflating balloon 32 to fully open fronds 16. As it is generally difficult to completely deflate the balloon, however, and a partially inflated balloon would be difficult to pass through the fronds, it will generally be preferable to use a second balloon catheter 130 for fully deforming fronds 16. When using the second balloon catheter 130, a second GW will usually be propositioned in the main vessel lumen MVL past the os O, as shown in FIGS. 11A and 11B. Further details of various protocols for deploying a stent having fronds or anchors, such as stent 10, are described in co-pending application Ser. No. 10/807,643.


In various embodiments for methods of the invention using delivery system 5, the physician can also make use of additional stent markers 22 and 24 positioned at the ends of stent 10. In one embodiment, one or more markers 22 are positioned at the ends of the fronds as is shown in FIGS. 9A and 9B. In this and related embodiments, the physician can utilize the markers to ascertain the position of the stent as well as the degree of deployment of the fronds (e.g., whether they are in captured, un-captured or deployed state). For example, in one embodiment of the deployment protocol, the physician could ascertain proper positioning of the stent by not only aligning the transition marker 20 with the Os opening O, but also look at the relative position of end markers 22 in main vessel lumen MVL to establish that the fronds are positioned far enough into the main vessel, have not been inadvertently positioned into another branch vessel/lumen and are not hung up on plaque or other vessel blockage. In this way, markers 20 and 22 provide the physician with a more accurate indication of proper stent positioning in a target location in a bifurcated vessel or lumen.


In another embodiment of a deployment protocol utilizing markers 22, the physician could determine the constraint state of the fronds (e.g. capture or un-captured), by looking at the position of the markers relative to balloon 30 and/or the distance between opposing fronds. In this way markers 22 can be used to allow the physician if the fronds were properly released from the constraining means prior to their deployment. In a related embodiment the physician could determine the degree of deployment of the fronds by looking at (e.g., eyeballing) the distance between markers 22 on opposing fronds using one or medical imaging methods known in the art (e.g., X-ray angiography). If one or more fronds are not deployed to their proper extent, the physician could deploy them further by repositioning (if necessary) and re-expanding balloon catheters 30 or 130.


While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Also, elements or steps from one embodiment can be readily recombined with one or more elements or steps from other embodiments. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.

Claims
  • 1. A prosthesis capable of being carried through a patient's vasculature over a delivery catheter and of being deployed at an Os, the prosthesis comprising: a radially expandable scaffold section; andat least two elongate members extending axially from a proximal end of the radially expandable scaffold section;a restraining device comprising a first circumferential span coupled with two of the elongate members and a second circumferential span coupled with two of the elongate members, the first and second circumferential spans each being spaced from the radially expandable scaffold section, the restraining device having a first configuration for maintaining the at least two elongate members in a collapsed configuration for advancement through the patient's vasculature, the restraining device also having a second configuration for permitting the at least two elongate members to expand to an expanded configuration, the restraining device having a proximal end located at or distal of a proximal end of the at least two elongate members, the restraining device having a distal end located on a proximal portion of the at least two elongate members,wherein at least a majority of expansion of the at least two elongate members from the collapsed configuration to the expanded configuration is provided by an outward pressure from the delivery catheter,wherein the scaffold section is configured to be not radially constrained by a structure that is separable from the delivery catheter when being carried through the patient's vasculature.
  • 2. A prosthesis as in claim 1, wherein the restraining device is expandable by the outward pressure from the delivery catheter to permit the at least two elongate members to be spaced farther apart from each other than when carried over the delivery catheter.
  • 3. A prosthesis as in claim 1, wherein the restraining device is configured to be detached from the at least two elongate members prior to expansion of the at least two elongate members.
  • 4. A prosthesis as in claim 1, wherein the restraining device is plastically deformable to release the at least two elongate members.
  • 5. A prosthesis as in claim 1, wherein the restraining device comprises a band disposed about the at least two elongate members.
  • 6. A prosthesis as in claim 1, wherein the restraining device comprises a radiopaque material.
  • 7. A vascular device, comprising: the prosthesis of claim 1; anda second prosthesis configured to be deployed in the vasculature, such that the at least two elongate members are disposed between the second prosthesis and a wall of the vasculature.
  • 8. A vascular device as in claim 7, wherein the second prosthesis is configured to be deployed between the at least two elongate members.
  • 9. A prosthesis as in claim 1, wherein the at least two elongate members are arranged to bend and rotate relative to an axis parallel to a central longitudinal axis of the radially expandable scaffold section such that the at least two elongate members can circumscribe a main vessel lumen to conform to a wall opposite the Os.
  • 10. A prosthesis as in claim 1, wherein the at least two elongate members comprise at least three elongate members extending from the radially expandable scaffold section.
  • 11. A prosthesis as in claim 1, wherein at least one of the elongate members has an axial length that is at least 1.5 times the width of the scaffold section prior to radial expansion.
  • 12. A prosthesis as in claim 1, wherein at least one of the elongate members has an axial length of at least about 2 mm.
  • 13. A prosthesis as in claim 1, wherein the radially expandable scaffold section has a first wall pattern and wherein the prosthesis has a region with a second wall pattern that is different from the first wall pattern, said second wall pattern permitting the at least two elongate members to both bend and rotate.
  • 14. A prosthesis as in claim 1, wherein at least one of the elongate members extends helically from the radially expandable scaffold section.
  • 15. A prosthesis as in claim 1, wherein at least one of the elongate members extends spirally from the radially expandable scaffold section.
  • 16. A prosthesis as in claim 1, wherein at least one of the elongate members extends in a serpentine pattern from the radially expandable scaffold section.
  • 17. A prosthesis capable of being carried through a patient's vasculature over a delivery catheter and of being deployed at an Os, the prosthesis comprising: a radially expandable scaffold section; andat least two elongate members extending axially from an end of the radially expandable scaffold section, the at least two elongate members having a low profile configuration and a higher profile configuration, the at least two elongate members transitioning from the low profile configuration to the higher profile configuration primarily under outward pressure from the delivery catheter;a capturing structure configured to prevent the at least two elongate members from divaricating from the low profile configuration as the prosthesis is advanced through the patient's vasculature, a proximal end of the capturing structure located at or distal of a proximal end of the at least two elongate members, a distal end of the capturing structure located on a proximal portion of the at least two elongate members,wherein the scaffold section is configured to be not radially constrained by a structure that is separable from the delivery catheter when being carried through the patient's vasculature.
  • 18. A prosthesis as in claim 17, wherein the capturing structure comprises a tether which circumscribes a proximal portion of the prosthesis.
  • 19. A prosthesis as in claim 18, wherein the tether is configured to be detachably attached to the at least two elongate members prior to expansion of the prosthesis.
  • 20. A prosthesis as in claim 17, wherein the capturing structure is configured to break upon expansion of the prosthesis.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Divisional of U.S. patent application Ser. No. 10/965,230 filed on Oct. 13, 2004, the full disclosure of which is incorporated by reference in its entirety herein.

US Referenced Citations (308)
Number Name Date Kind
4950227 Savin et al. Aug 1990 A
4958634 Jang Sep 1990 A
4994071 MacGregor Feb 1991 A
5071406 Jang Dec 1991 A
5074845 Miraki et al. Dec 1991 A
5102417 Palmaz Apr 1992 A
5226889 Sheiban Jul 1993 A
5304132 Jang Apr 1994 A
5342387 Summers Aug 1994 A
5383892 Cardon et al. Jan 1995 A
5395333 Brill Mar 1995 A
5415635 Bagaoisan et al. May 1995 A
5507769 Marin et al. Apr 1996 A
5522882 Gaterud et al. Jun 1996 A
5540712 Kleshinski et al. Jul 1996 A
5575817 Martin Nov 1996 A
5593442 Klein Jan 1997 A
5607444 Lam Mar 1997 A
5609605 Marshall et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5613980 Chauhan Mar 1997 A
5628783 Quiachon et al. May 1997 A
5632762 Myler May 1997 A
5632772 Alcime et al. May 1997 A
5632840 Campbell May 1997 A
5645560 Crocker et al. Jul 1997 A
5656036 Palmaz Aug 1997 A
5658251 Ressemann et al. Aug 1997 A
5662608 Imran et al. Sep 1997 A
5669924 Shaknovich Sep 1997 A
5669932 Fischell et al. Sep 1997 A
5711754 Miyata et al. Jan 1998 A
5713917 Leonhardt et al. Feb 1998 A
5718712 Bonnal et al. Feb 1998 A
5720724 Ressemann et al. Feb 1998 A
5720735 Dorros Feb 1998 A
5741325 Chaikof et al. Apr 1998 A
5749825 Fischell et al. May 1998 A
5749851 Wang May 1998 A
5749890 Shaknovich May 1998 A
5755734 Richter et al. May 1998 A
5755735 Richter et al. May 1998 A
5755771 Penn et al. May 1998 A
5755778 Kleshinski May 1998 A
5755781 Jayaraman May 1998 A
5788708 Hegde et al. Aug 1998 A
5810871 Tuckey et al. Sep 1998 A
5824052 Khosravi et al. Oct 1998 A
5827320 Richter et al. Oct 1998 A
5843116 Crocker et al. Dec 1998 A
5855598 Pinchuk Jan 1999 A
5860998 Robinson et al. Jan 1999 A
5868777 Lam Feb 1999 A
5868783 Tower Feb 1999 A
5891191 Stinson Apr 1999 A
5893887 Jayaraman Apr 1999 A
5897588 Hull et al. Apr 1999 A
5906640 Penn et al. May 1999 A
5906641 Thompson et al. May 1999 A
5922019 Hankh et al. Jul 1999 A
5961546 Robinson et al. Oct 1999 A
5964771 Beyar et al. Oct 1999 A
5967971 Bolser Oct 1999 A
5968089 Krajicek Oct 1999 A
5972017 Berg et al. Oct 1999 A
5976181 Whelan et al. Nov 1999 A
5980532 Wang Nov 1999 A
6004347 McNamara et al. Dec 1999 A
6017363 Hojeibane Jan 2000 A
6027486 Crocker et al. Feb 2000 A
6027517 Crocker et al. Feb 2000 A
6033434 Borghi Mar 2000 A
6033435 Penn et al. Mar 2000 A
6048361 Von Oepen Apr 2000 A
6051020 Goiechea et al. Apr 2000 A
6053913 Tu et al. Apr 2000 A
6053941 Lindenberg et al. Apr 2000 A
6056775 Borghi et al. May 2000 A
6056776 Lau et al. May 2000 A
6066155 Amann et al. May 2000 A
6066168 Lau et al. May 2000 A
6068654 Berg et al. May 2000 A
6068655 Seguin et al. May 2000 A
6077297 Robinson et al. Jun 2000 A
6090127 Globerman Jul 2000 A
6090133 Richter et al. Jul 2000 A
6096071 Yadav Aug 2000 A
6096073 Webster et al. Aug 2000 A
6099497 Adams et al. Aug 2000 A
6099560 Penn et al. Aug 2000 A
6113607 Lau et al. Sep 2000 A
6120523 Crocker et al. Sep 2000 A
6127597 Beyar et al. Oct 2000 A
6129738 Lashinski et al. Oct 2000 A
6129754 Kanesaka et al. Oct 2000 A
6156052 Richter et al. Dec 2000 A
6159219 Ren Dec 2000 A
6159238 Killion et al. Dec 2000 A
6162243 Gray et al. Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6168617 Blaeser et al. Jan 2001 B1
6183509 Dibie Feb 2001 B1
6200325 Durcan et al. Mar 2001 B1
6206910 Berry et al. Mar 2001 B1
6210429 Vardi et al. Apr 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221080 Power Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6221098 Wilson et al. Apr 2001 B1
6231543 Hegde et al. May 2001 B1
6241738 Dereume Jun 2001 B1
6241744 Imran et al. Jun 2001 B1
6254593 Wilson Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6264682 Wilson et al. Jul 2001 B1
6264686 Rieu et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270525 Letendre et al. Aug 2001 B1
6280412 Pederson, Jr. et al. Aug 2001 B1
6287315 Wijeratne et al. Sep 2001 B1
6287336 Globerman et al. Sep 2001 B1
6290728 Phelps et al. Sep 2001 B1
6293964 Yadav Sep 2001 B1
6325826 Vardi et al. Dec 2001 B1
6331186 Wang et al. Dec 2001 B1
6344052 Greenan et al. Feb 2002 B1
6346089 Dibie Feb 2002 B1
6346118 Baker et al. Feb 2002 B1
6352551 Wang Mar 2002 B1
6361544 Wilson et al. Mar 2002 B1
6383212 Durcan et al. May 2002 B2
6383213 Wilson et al. May 2002 B2
6387120 Wilson et al. May 2002 B2
6391032 Blaeser et al. May 2002 B2
6395008 Ellis et al. May 2002 B1
6402778 Wang Jun 2002 B2
6409741 Crocker et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6409755 Vrba Jun 2002 B1
6409757 Trout, III et al. Jun 2002 B1
6428567 Wilson et al. Aug 2002 B2
6436104 Hojeibane Aug 2002 B2
6436134 Richter et al. Aug 2002 B2
6440165 Richter et al. Aug 2002 B1
6451050 Rudakov et al. Sep 2002 B1
6478814 Wang et al. Nov 2002 B2
6482211 Choi Nov 2002 B1
6482227 Solovay Nov 2002 B1
6485509 Killion et al. Nov 2002 B2
6488700 Klumb et al. Dec 2002 B2
6508836 Wilson et al. Jan 2003 B2
6517558 Gittings et al. Feb 2003 B2
6524335 Hartley et al. Feb 2003 B1
6540779 Richter et al. Apr 2003 B2
6547813 Stiger et al. Apr 2003 B2
6554856 Doorly et al. Apr 2003 B1
6562061 Wang et al. May 2003 B1
6565597 Fearnot et al. May 2003 B1
6572649 Berry et al. Jun 2003 B2
6579312 Wilson et al. Jun 2003 B2
6579314 Lombardi et al. Jun 2003 B1
6582394 Reiss et al. Jun 2003 B1
6589274 Stiger et al. Jul 2003 B2
6596020 Vardi et al. Jul 2003 B2
6599316 Vardi et al. Jul 2003 B2
6607552 Hanson Aug 2003 B1
6626934 Blaeser et al. Sep 2003 B2
6637107 Yasuhara et al. Oct 2003 B2
6652580 Chuter et al. Nov 2003 B1
6656215 Yanez et al. Dec 2003 B1
6656216 Hossainy et al. Dec 2003 B1
6663665 Shaolian et al. Dec 2003 B2
6663666 Quiachon et al. Dec 2003 B1
6673104 Barry Jan 2004 B2
6673106 Mitelberg et al. Jan 2004 B2
6673107 Brandt et al. Jan 2004 B1
6682557 Quiachon et al. Jan 2004 B1
6706062 Vardi et al. Mar 2004 B2
6726714 DiCaprio et al. Apr 2004 B2
6740113 Vrba May 2004 B2
6756094 Wang et al. Jun 2004 B1
6764504 Wang et al. Jul 2004 B2
6770092 Richter Aug 2004 B2
6790224 Gerberding Sep 2004 B2
6805697 Helm et al. Oct 2004 B1
6805702 Chen et al. Oct 2004 B1
6824553 Samson et al. Nov 2004 B1
6830575 Stenzel et al. Dec 2004 B2
6843802 Villalobos et al. Jan 2005 B1
6852116 Leonhardt et al. Feb 2005 B2
6872215 Crocker et al. Mar 2005 B2
6887268 Butaric et al. May 2005 B2
6911038 Mertens et al. Jun 2005 B2
6926690 Renati Aug 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6986786 Smith Jan 2006 B1
7476243 Eidenschink Jan 2009 B2
7481834 Kaplan et al. Jan 2009 B2
7578841 Yadin et al. Aug 2009 B2
7708772 Wilson et al. May 2010 B2
7717953 Kaplan et al. May 2010 B2
7731747 Kaplan et al. Jun 2010 B2
7758630 Davis et al. Jul 2010 B2
7972369 Kaplan et al. Jul 2011 B2
7972372 Davis et al. Jul 2011 B2
8083791 Kaplan et al. Dec 2011 B2
8109987 Kaplan et al. Feb 2012 B2
8187314 Davis et al. May 2012 B2
8252038 Kaplan et al. Aug 2012 B2
8257432 Kaplan et al. Sep 2012 B2
8366763 Davis et al. Feb 2013 B2
8382818 Davis et al. Feb 2013 B2
8529618 Davis et al. Sep 2013 B2
8641751 Davis et al. Feb 2014 B2
8641755 Davis et al. Feb 2014 B2
8672994 Kaplan et al. Mar 2014 B2
20010000350 Durcan et al. Apr 2001 A1
20010008976 Wang Jul 2001 A1
20010011188 Berry et al. Aug 2001 A1
20010020181 Layne Sep 2001 A1
20010023356 Raz et al. Sep 2001 A1
20010029396 Wilson et al. Oct 2001 A1
20010037137 Vardi et al. Nov 2001 A1
20010039448 Dibie Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20020022874 Wilson Feb 2002 A1
20020026232 Marotta et al. Feb 2002 A1
20020032478 Boekstegers et al. Mar 2002 A1
20020058984 Butaric et al. May 2002 A1
20020058993 Landau et al. May 2002 A1
20020077692 Besselink Jun 2002 A1
20020111619 Keast et al. Aug 2002 A1
20020116047 Vardi et al. Aug 2002 A1
20020151959 Von Oepen Oct 2002 A1
20020156516 Vardi et al. Oct 2002 A1
20020156525 Smith et al. Oct 2002 A1
20020165602 Douglas et al. Nov 2002 A1
20020169498 Kim et al. Nov 2002 A1
20020173840 Brucker et al. Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020183780 Wang Dec 2002 A1
20020193862 Mitelberg et al. Dec 2002 A1
20020193868 Mitelberg et al. Dec 2002 A1
20020198559 Mistry et al. Dec 2002 A1
20030083734 Friedrich et al. May 2003 A1
20030097171 Elliott May 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030125797 Chobotov et al. Jul 2003 A1
20030125799 Limon Jul 2003 A1
20030199967 Hartley et al. Oct 2003 A1
20040015227 Vardi et al. Jan 2004 A1
20040024441 Bertolino et al. Feb 2004 A1
20040054362 Lopath et al. Mar 2004 A1
20040054396 Hartley et al. Mar 2004 A1
20040073250 Pederson, Jr. et al. Apr 2004 A1
20040093058 Cottone et al. May 2004 A1
20040106985 Jang Jun 2004 A1
20040133261 Bigus et al. Jul 2004 A1
20040133268 Davidson et al. Jul 2004 A1
20040138730 Mitelberg et al. Jul 2004 A1
20040138734 Chobotov et al. Jul 2004 A1
20040138737 Davidson et al. Jul 2004 A1
20040143209 Liu et al. Jul 2004 A1
20040158306 Mitelberg et al. Aug 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040230287 Hartley et al. Nov 2004 A1
20040230293 Yip et al. Nov 2004 A1
20040249434 Andreas et al. Dec 2004 A1
20040254627 Thompson et al. Dec 2004 A1
20040260378 Goshgarian Dec 2004 A1
20040260383 Stelter et al. Dec 2004 A1
20050010278 Vardi et al. Jan 2005 A1
20050015108 Williams et al. Jan 2005 A1
20050049678 Cocks et al. Mar 2005 A1
20050137621 Stahl et al. Jun 2005 A1
20050154447 Goshgarian Jul 2005 A1
20050159803 Lad et al. Jul 2005 A1
20050165469 Hogendijk et al. Jul 2005 A1
20050192656 Eidenschink Sep 2005 A1
20050203563 Pederson, Jr. et al. Sep 2005 A9
20050209674 Kutscher et al. Sep 2005 A1
20050234536 Mitelberg et al. Oct 2005 A1
20050251195 Wang Nov 2005 A1
20050261722 Crocker et al. Nov 2005 A1
20050288769 Globerman Dec 2005 A1
20060025849 Kaplan et al. Feb 2006 A1
20060064064 Jang Mar 2006 A1
20060079956 Eigler et al. Apr 2006 A1
20060116748 Kaplan et al. Jun 2006 A1
20060178733 Pinchuk et al. Aug 2006 A1
20070203571 Kaplan et al. Aug 2007 A1
20070213803 Kaplan et al. Sep 2007 A1
20070213804 Kaplan et al. Sep 2007 A1
20070288082 Williams Dec 2007 A1
20080015610 Kaplan et al. Jan 2008 A1
20080015678 Kaplan et al. Jan 2008 A1
20080183269 Kaplan et al. Jul 2008 A2
20080294240 Casey Nov 2008 A1
20090163988 Kaplan et al. Jun 2009 A1
20090163999 Kaplan et al. Jun 2009 A1
20090326641 Davis et al. Dec 2009 A1
20100222870 Kaplan et al. Sep 2010 A1
20110004291 Davis et al. Jan 2011 A1
20110004292 Davis et al. Jan 2011 A1
20130282106 Davis et al. Oct 2013 A1
20130338751 Davis et al. Dec 2013 A1
Foreign Referenced Citations (32)
Number Date Country
0712614 May 1996 EP
0505686 Nov 1996 EP
0540290 Jan 1998 EP
0876805 Nov 1998 EP
0959811 Jan 1999 EP
1325715 Sep 2003 EP
1325716 Sep 2003 EP
1325717 Sep 2003 EP
1362564 Nov 2003 EP
1433441 Jun 2004 EP
1 512 381 Mar 2005 EP
H09-117511 May 1997 JP
WO 9638101 Dec 1996 WO
WO 9717101 May 1997 WO
WO 9746175 Dec 1997 WO
WO 9819629 May 1998 WO
WO 9824503 Jun 1998 WO
WO 0015147 Mar 2000 WO
WO 0069367 Nov 2000 WO
WO 0247580 Jun 2002 WO
WO 0249538 Jun 2002 WO
WO 03020173 Mar 2003 WO
WO 03039626 May 2003 WO
WO 03057079 Jul 2003 WO
WO 2004026180 Apr 2004 WO
WO 2004058100 Jul 2004 WO
WO 2004089249 Oct 2004 WO
WO 2004091428 Oct 2004 WO
WO 2004103217 Dec 2004 WO
WO 2005041810 May 2005 WO
WO 2012071542 May 2012 WO
WO 2013162724 Oct 2013 WO
Non-Patent Literature Citations (50)
Entry
Prosecution history including the Office Actions mailed Dec. 5, 2008, Apr. 2, 2009, Nov. 2, 2009 and Apr. 15, 2010, the Amendments filed Jan. 29, 2009, Jun. 30, 2009, Dec. 21, 2009, May 14, 2010, and Apr. 25, 2011, and the Notice of Allowances mailed Jun. 14, 2010 and Jan. 25, 2011.
Prosecution history including the Office Actions mailed Dec. 5, 2008, Mar. 20, 2009, Oct. 15, 2009, and Jun. 9, 2010 and the Amendments filed Jan. 29, 2009, Jun. 30, 2009, Dec. 15, 2009, Sep. 9, 2010, and Feb. 16, 2011, and the Notice of Allowance mailed Nov. 16, 2010.
Prosecution history including the Office Actions mailed Apr. 7, 2008, Oct. 10, 2008, and Mar. 17, 2009, and Oct. 27, 2009 and the Amendments filed Jul. 14, 2008, Nov. 20, 2008, Jun. 30, 2009, and Mar. 1, 2010.
Prosecution history including the Office Actions mailed Apr. 7, 2009, and Oct. 27, 2009 and the Amendments filed Jul. 6, 2009 and Mar. 1, 2010.
Prosecution history including the Office Actions mailed Mar. 24, 2008, Dec. 1, 2008, Dec. 28, 2009 and Jun. 24, 2010, the Amendments filed Aug. 21, 2008, and Mar. 25, 2010 and the Appeal Brief filed Sep. 17, 2009 and the Notice of Allowance mailed Feb. 24, 2011.
Prosecution history including the Office Actions mailed Jun. 17, 2009, Dec. 9, 2009, and Mar. 7, 2011 and the Amendments filed Aug. 19, 2009, Feb. 9, 2010, and Nov. 29, 2010.
Prosecution history including the Office Action mailed May 3, 2010, the Amendment filed Jun. 8, 2010, and the Notice of Allowance mailed Aug. 12, 2010 and Apr. 12, 2011.
Prosecution history including the Office Actions mailed Apr. 11, 2008, Oct. 7, 2008, Mar. 20, 2009 and Nov. 23, 2009 and the Amendments filed Jul. 14, 2008, Nov. 17, 2008, Jul. 6, 2009, Mar. 23, 2010, and Mar. 10, 2011.
Prosecution history including the Office Actions mailed Jun. 21, 2010 and Mar. 21, 2011 and the Amendments filed Dec. 17, 2010.
Prosecution history including the Office Actions mailed Aug. 26, 2010 and Jan. 19, 2011 and the Amendment filed Nov. 24, 2010 and Apr. 19, 2011.
Prosecution file history including the Office Actions mailed Jul. 13, 2010 and Mar. 7, 2011 and the Amendment filed Dec. 13, 2010.
U.S. Appl. No. 12/780,742 and its prosecution history.
U.S. Appl. No. 12/829,193 and its prosecution history.
U.S. Appl. No. 12/829,217 and its prosecution history.
A New Team to Fight Arterial Disease, Building Innovation & Construction Technology, No. 10, Dec. 1999, http://www.cmit.csiro.au/innovation/1999-12/arterial.htm.
Endovascular Grafts: History of Minimally Invasive Treatment of Vascular Disease, Timothy A.M. Chuter, Endoluminal Vascular Prostheses, pp. 3-17, 1995.
Esophageal Strictures: Treatment with a New Design of Modified Gianturco Stent, Ho. Young Song, M.D. et al., Radiology, vol. 184, No. 3, pp. 729-734 Sep. 1992.
Protection of Side-Branches in Coronary Lesions With a New Stent Design, Stephan Baldus, MD et al., Catherization and Cardiovascular Diagnosis, vol. 45: No. 4, 456-459, Dec. 1998.
Self-expanding Stainless Steel Biliary Stents, Harold G. Coons, MD, Radiology, vol. 170, No. 3, Part 2, pp. 979-983, Mar. 1989.
Serruys, Patrick W et al.; Handbook of Coronary Stents; Jan. 15, 2002; pp. 130-131; Martin Dunitz, Ltd.; London, UK.
The Impact of Stent Design on Proximal Stent-graft Fixation in the Abdominal Aorta: an Experimental Study, T. Resch et al., European Journal of Vascular and Endovascular Surgery, vol. 20, No. 2, pp. 190-195, Aug. 2000.
The Zenith endoluminal stent-graft system: suprarenal fixation, safety features, modular components, fenestration and custom crafting, Michael M.D. Lawrence-Brown et al., Vascular and Endovascular Surgical Techniques, Fourth Edition, pp. 219-223, 2001.
International Search Report and Written Opinion in PCT Application No. PCT/US04/10591 dated Mar. 11, 2005 in 6 pages.
International Search Report in PCT Application No. PCT/US05/36987dated Jun. 5, 2006.
International Search Report and Written Opinion in PCT Application No. PCT/US07/85429 dated Jun. 2, 2008 in 10 pages.
Supplemental European Search Report for Application No. EP 05 81 2396 mailed Nov. 18, 2009 in 7 pages.
Supplementary European Search Report for Application No. EP 04759166.4 dated Mar. 5, 2007 in 4 pages.
European Patent Office Communication (first substantive examination report) in Application No. 04 759 166.4-1526 dated Apr. 30, 2007 in 3 pages.
International Search Report and Written Opinion in Application No. PCT/US10/40962 dated Oct. 13, 2010, in 14 pages.
Prosecution history including the Amendment filed July Mar. 10, 2011.
Prosecution history including the Amendment filed Mar. 10, 2011.
Prosecution history including the Office Actions mailed, Jul. 11, 2011, and Nov. 28, 2011 and the Amendments filed Jun. 7, 2011, Oct. 11, 2011, Feb. 27, 2012, and Mar. 30, 2012.
Prosecution history including the Amendments filed Jun. 21, 2011, Dec. 19, 2011, and Apr. 4, 2012 and the Notice of Allowance mailed Jan. 9, 2012.
International Search Report and Written Opinion in Application No. PCT/US11/062102 dated Feb. 29, 2012, in 14 pages.
Prosecution history including the Amendment filed Feb. 15, 2012.
Prosecution file history including the Amendment filed Jun. 7, 2011.
Prosecution history including the Office Action mailed Dec. 29, 2011 and the Amendment filed Mar. 28, 2012.
Prosecution history including the Office Action mailed Dec. 8, 2011.
Prosecution history including the Office Action mailed Dec. 23, 2011.
Prosecution history including the Office Action mailed Dec. 16, 2013 and Apr. 18, 2014, the Amendments filed Mar. 17, 2014 and Jun. 18, 2014, and the Notice of Allowance mailed Jul. 1, 2014.
Prosecution history including the Office Action mailed May 1, 2013.
Prosecution file history including the Notice of Allowance mailed May 10, 2013.
Extended European Search Report in Application EP12000249.8 dated May 11, 2012, in 7 pages.
Prosecution file history including Amendment filed Apr. 6, 2012.
Prosecution history including the Amendment filed May 22, 2012.
Prosecution history including the Amendment filed Sep. 20, 2012 and the Notice of Allowance mailed Oct. 2, 2012.
Prosecution history including the Notice of Allowance mailed Oct. 4, 2012.
International Search Report and Written Opinion in Application No. PCT/US2013/030246 dated Jul. 4, 2013, in 8 pages.
Prosecution history including the Amendments filed Jul. 23, 2013.
Prosecution file history including the Amendments filed Aug. 2, 2013.
Related Publications (1)
Number Date Country
20100211160 A1 Aug 2010 US
Divisions (1)
Number Date Country
Parent 10965230 Oct 2004 US
Child 12768562 US